Loading…
← CockpitCompetitor Analysis › 300206.SZ Edan Instruments, Inc. Class AOpen in the cockpit ↗

Edan Instruments, Inc. Class A300206.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese medical-device exporter making patient monitors, ultrasound, ECG machines and veterinary diagnostic devices.

≈ A Chinese Mindray-lite, exports patient monitors/ultrasound globallyMomentum leader 81
Mkt cap
$1.00B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$10.1M
20-day average traded
Fwd P/E
18.0×
forward earnings
ROIC−WACC
+18.9 pp
WACC 9.5%
Hurdle
+10 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥11.60
1D-2.4%
1W-1.7%
1M+4.6%
3M-4.4%
6M-19.4%
YTD-9.3%
1Y-16.0%
ATR %2.9%
52w lowhigh30.9% off high

What Edan Instruments does

Chinese medical-device exporter making patient monitors, ultrasound, ECG machines and veterinary diagnostic devices.

Sells mostly through local distributors abroad rather than its own foreign sales teams, and wins part of its business in government hospital tenders in emerging markets, so public health budgets and currency moves affect results.

In one line: A Chinese Mindray-lite, exports patient monitors/ultrasound globally.

Products and services

  • Patient monitors
  • Ultrasound imaging systems
  • ECG machines
  • Veterinary diagnostic devices

Customers

  • Hospitals worldwide (export-heavy)
  • Veterinary clinics

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Patient monitoring, ultrasound…

What could go right

  • Emerging-market hospital equipment demand

What could go wrong

  • Pricing competition from larger global vendors

Moat: narrow (brand, distribution). Established export distribution network across emerging markets.

Headquarters: Shenzhen, Guangdong, China · Founded: 1995 · Employees: 2,475

Named competitors

Edan Instruments at a glance

Size Edan Instruments (300206.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.00B, the 2152nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.60 on 18 Nov 2026.

Performance Over six months the shares fell 19.4%, against -6.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 13.7% over the last twelve months (peer median +10.2%); the operating margin is 17.4% (peer median 11.0%).

Valuation It trades at 18.0× forward earnings against a peer median of 19.0× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 18.9 points above its cost of capital (9.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 92300206.SZ 84
Six months, rebased to 100: Edan Instruments against the median of its 20 peers (local-currency closes).

Edan Instruments financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.16BCN¥1.98BCN¥1.82BCN¥1.92BCN¥1.72B
Revenue growth—+9%-5%+11%—
Gross profitCN¥1.28BCN¥1.12BCN¥1.01BCN¥1.06BCN¥927M
EBITDAn/aCN¥353MCN¥197MCN¥241MCN¥249M
Net incomeCN¥370MCN¥306MCN¥162MCN¥221MCN¥233M
Free cash flowCN¥349MCN¥273MCN¥298MCN¥103MCN¥299M
Capital expenditureCN¥60.9MCN¥84.7MCN¥77.7MCN¥51.1MCN¥42.4M
Total debtCN¥27.2MCN¥30.5MCN¥17.8MCN¥17.7MCN¥10.4M

Quarterly statements and history in the cockpit →

Edan Instruments competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%CBLL3006856523300143301021600055EUZCSTL77303046IRMDSFLSIBN6886227780290650301101IART214150300206.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Edan Instruments is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×3006856523300143EUZ77303046IRMDSFL7780301101IART214150300206.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Edan Instruments is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%3006856523300143301021EUZCSTL77303046IRMDSFL290650214150300206.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Edan Instruments is the large dot.

Edan Instruments competitors and peer comparison

Head to head with its named competitors (300206.SZ vs 300760.SZ vs GEHC vs PHIA.AS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Edan Instruments 300206.SZ$1.00B-19%+14%17%18.0×6.9%
Shenzhen Mindray Bio-Medical Electronics 300760.SZ$33.6B+15%+5%28%27.3×1.0%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%
Koninklijke Philips PHIA.AS$29.0B+17%-1%10%16.4×5.9%
Sonoscape Medical 300633.SZ$1.31B-10%+18%4%34.7×n/a

How Edan Instruments compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Edan Instruments against its 20 peers (data as of 18 Nov 2026)
Measure300206.SZPeer medianRank in peer set
1-month return+4.6%-4.7%7th highest of 21
6-month return-19.4%-6.8%6th lowest of 20
Distance from 52-week high-30.9%-27.5%9th lowest of 21
Revenue growth (TTM)+13.7%+10.2%9th highest of 20
Operating margin17.4%11.0%9th highest of 21
Forward P/E18.0×19.0×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)6.9%6.8%8th least demanding of 15
Growth delivered (Del g)-2.9%+11.9%lowest of 15
Hurdle (Req g minus delivered)+9.8 pp-3.2 pp4th most demanding of 15
ROIC minus cost of capital+18.9 pp+2.8 pp5th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a

Questions

Who are Edan Instruments's main competitors?
Named competitors: Mindray (300760.SZ), GE HealthCare (GEHC), Philips (PHIA.AS), Sonoscape Medical (300633.SZ). The cockpit's measured peer set (industry) also includes Ceribell (CBLL), Amoy Diagnostics (300685.SZ), PHC (6523.T), INKON Life Technology (300143.SZ), Inno Laser Technology (301021.SZ), Beijing Wandong Medical Technology (600055.SS).
Is Edan Instruments expensive compared with its peers?
On forward p/e it trades at 18.0× against a peer median of 19.0×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Edan Instruments stock performed?
Over six months to 18 Nov 2026 the shares returned -19.4% against -6.8% for the median peer; over one year -16.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.